<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;TP53&lt;/i&gt;
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        TP53
       </i>
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         TP53
        </i>
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            D Gareth Evans, MD, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Demetra Georgiou, Principal Genetic Counsellor (GCRB)
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H15513607">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          TP53
         </em>
         gene encodes the tumor suppressor protein p53, which has been designated the guardian of the genome. It is responsible for much of the modern understanding of tumor suppressor function.
        </p>
        <p>
         Of all the genes associated with inherited cancer syndromes,
         <em>
          TP53
         </em>
         may be the most challenging to address clinically, for reasons discussed below. Other considerations such as somatic
         <em>
          TP53
         </em>
         mutations in cancer and indications for testing are discussed separately [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'UpToDate topics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2666193350">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H1634907503">
         <span class="h2">
          How to read the report
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline
         <em>
          TP53
         </em>
         testing has major implications for clinical care. Early involvement of an expert in hereditary cancer syndromes is essential.
        </p>
        <p>
         The tables define terms used in genetic test reports  (
         <a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">
          table 1
         </a>
         ) and list general caveats to consider when reviewing results  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Important caveats specific to
         <em>
          TP53
         </em>
         include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Results should be reviewed to ensure accurate sequence data and interpretation
         <strong>
          before
         </strong>
         the implications are reviewed with the tested individual, since potential consequences of a positive or negative result are especially meaningful  (
         <a class="graphic graphic_algorithm graphicRef130071" href="/z/d/graphic/130071.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The entire
         <em>
          TP53
         </em>
         gene should be sequenced, rather than testing for selected variants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sometimes sequencing of coding regions may be adequate; in others, sequencing of coding and noncoding regions may be required.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sensitive techniques should be used to test for copy number variants, as single and multiple exon deletions (and rarely, duplications) also occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One exception is a known familial disease variant; at-risk relatives can be tested exclusively for the specific variant  (
         <a class="graphic graphic_algorithm graphicRef130071" href="/z/d/graphic/130071.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'First-degree relatives (testing and counseling)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somatically acquired
         <em>
          TP53
         </em>
         variants carry substantially different implications from germline (constitutional) variants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Somatic
         <em>
          TP53 varian
         </em>
         ts are common in many solid tumor types, as the p53 tumor suppressor plays a major role in coupling DNA damage with cell cycle delay and apoptosis [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Somatic
         <em>
          TP53
         </em>
         variants frequently arise in bone marrow, especially in older individuals, and these can lead to clonal hematopoiesis. Clonal hematopoiesis of indeterminate potential (CHIP) can produce allele frequencies as high as 50 percent in lymphocytes [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107866.html" rel="external">
          "Clonal hematopoiesis of indeterminate potential (CHIP) and related disorders of clonal hematopoiesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the first identification of a variant is from tumor tissue or CHIP, at least two tissues need to be tested to establish whether a germline variant exists (peripheral blood lymphocytes plus skin fibroblasts or tumor plus a somatic tissue).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         De novo germline
         <em>
          TP53
         </em>
         variants and mosaicism can also occur, further emphasizing the need for careful assessment by a specialist. (See
         <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">
          "Genetics: Glossary of terms", section on 'Mosaicism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H669449925">
         <span class="h2">
          Classification of variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Variants identified by genetic testing are classified into one of five categories of pathogenicity designated by the American College of Medical Genetics (ACMG)  (
         <a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">
          table 3
         </a>
         ), depending on the confidence in their association with a disorder [
         <a href="#rid5">
          5
         </a>
         ]. The classification is based on research demonstrating the variant can cause disease, not the likelihood that an individual with the variant will develop disease (ie, strength of association, not disease penetrance).
        </p>
        <p>
         Stricter criteria than those specified by ACMG are used to further parse
         <em>
          TP53
         </em>
         variant interpretation. The ClinGen working group criteria require at least two functional tests that support pathogenicity, supportive clinical pathology data, and association with a positive personal or family history of heritable
         <em>
          TP53
         </em>
         -related cancer syndrome [
         <a href="#rid6">
          6
         </a>
         ]. All individuals in a particular category should not be lumped together, as not all findings in a category carry the same management implications. A genetics professional or hereditary cancer expert should be involved.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenic and likely pathogenic
         </strong>
         – Pathogenic variants (PV) and likely pathogenic variants (LPV) reflect &gt;90 percent confidence of disease association. LPV are treated the same as PV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PV and LPV must be stringently assessed against ACMG criteria and (when they become available) ACMG/Association for Molecular Pathology (AMP) criteria, so as not to misdiagnose a
         <em>
          TP53
         </em>
         syndrome. Without this stringent assessment, as many as 1 in 500 variants in the population gnomAD database could be considered PV or LPV, whereas a more stringent approach reduces this to approximately 1 in 5000 [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          TP53
         </em>
         PV and LPV are further subdivided by their effect on p53 function. Dominant-negative mutations can have more severe phenotypes than variants that do not block normal p53 function. (See
         <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">
          "Genetics: Glossary of terms", section on 'Dominant negative'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VUS
         </strong>
         – Variants of uncertain significance (VUS) lack sufficient evidence to determine disease causation. VUS may be reclassified as pathogenic or benign as family studies and bench research accrue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gradations in
         <em>
          TP53
         </em>
         VUS have major implications for risk. A genetics expert will review these details to determine optimal management. Per ACMG/AMP criteria, several factors can be reviewed, including segregation studies, functional studies, and in silico analysis. A ClinGen
         <em>
          TP53
         </em>
         Variant Curation Expert Panel has published guidance on how to apply criteria [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign and likely benign
         </strong>
         – Benign and likely benign variants carry high confidence of no disease association. These typically are not reported (or are reported as negative).
        </p>
        <p>
        </p>
        <p>
         Laboratories vary in their expertise in interpreting
         <em>
          TP53
         </em>
         variants, underscoring the importance of specialist input before making treatment decisions.
        </p>
        <p class="headingAnchor" id="H3605823105">
         <span class="h2">
          Disease associations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Germline PV and LPV in
         <em>
          TP53
         </em>
         are associated with increased risk of several cancers including (but not limited to):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soft tissue sarcomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteosarcomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adrenocortical carcinomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central nervous system tumors (mainly glial, choroid plexus, and medulloblastoma)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast cancers in young females (≤30 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute leukemias or myelodysplastic syndromes (MDS), often following treatment for one of the above solid tumors
        </p>
        <p>
        </p>
        <p>
         Affected individuals are heterozygous for a PV or LPV in
         <em>
          TP53
         </em>
         . Tumors typically show somatic loss or mutation of the second (normal) allele; other changes including loss of the germline PV can occur. The first cancer diagnosis is generally in childhood (one-fifth before 5 years; two-fifths before 18 years); often multiple cancers develop by adulthood [
         <a href="#rid10">
          10
         </a>
         ]. The risks differ depending on the variant; it is important to review the results and personal and family history before determining an individual's personal risk spectrum. (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome", section on 'Spectrum of malignancies and age at onset'
         </a>
         .)
        </p>
        <p>
         Prior to widespread availability of genetic testing, clinical criteria were used to identify individuals who should undergo genetic counseling and
         <em>
          TP53
         </em>
         testing. The classic Li-Fraumeni syndrome (LFS) criteria included an autosomal dominant cancer syndrome with sarcoma before age 45 in the proband  (
         <a class="graphic graphic_table graphicRef79296" href="/z/d/graphic/79296.html" rel="external">
          table 4
         </a>
         ). The Chompret criteria  (
         <a class="graphic graphic_table graphicRef58516" href="/z/d/graphic/58516.html" rel="external">
          table 5
         </a>
         ) are broader but miss some individuals with a germline PV or LPV in
         <em>
          TP53
         </em>
         . Chompret criteria may also apply to individuals with early-onset breast cancer due to non-
         <em>
          TP53
         </em>
         genetic cause. (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes"
         </a>
         .)
        </p>
        <p>
         The diagnosis has since been broadened to heritable
         <em>
          TP53
         </em>
         -related cancer syndrome (h
         <em>
          TP53
         </em>
         rc), which includes a wider range of presentations, as outlined in a 2020 European Reference Network (ERN) guideline [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3698250008">
         <span class="h1">
          PREVENTIVE CARE
         </span>
        </p>
        <p class="headingAnchor" id="H1973325159">
         <span class="h2">
          Cancer surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early identification of cancers is paramount to reduce disease and treatment morbidities and to increase the chance for curative therapy [
         <a href="#rid10">
          10,12,13
         </a>
         ].
        </p>
        <p>
         Individuals with a pathogenic variant (PV) or likely pathogenic variant (LPV) in
         <em>
          TP53
         </em>
         require a comprehensive surveillance program to identify new cancers  (
         <a class="graphic graphic_algorithm graphicRef130071" href="/z/d/graphic/130071.html" rel="external">
          algorithm 1
         </a>
         ). The same program may be offered to those with a family history consistent with heritable
         <em>
          TP53
         </em>
         -related cancer syndrome (h
         <em>
          TP53
         </em>
         rc) when a familial variant cannot be identified after review by a genetics clinician. Involvement of a hereditary cancer syndrome expert is essential.
        </p>
        <p>
         Surveillance may differ depending on the specific
         <em>
          TP53
         </em>
         variant and/or the family history and should be coordinated with a cancer geneticist, cancer genetic counselor, or hereditary cancer expert [
         <a href="#rid10">
          10,12,13
         </a>
         ]. The table summarizes suggested screenings  (
         <a class="graphic graphic_table graphicRef130055" href="/z/d/graphic/130055.html" rel="external">
          table 6
         </a>
         ). These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical examination; skin examination from 18 years onward
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whole-body magnetic resonance imaging (MRI; without contrast), annually starting at birth (may require sedation or general anesthesia in young children)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain MRI (first with contrast, subsequently without), annually starting at birth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal ultrasound from birth to 18 years; biochemical testing for adrenocortical carcinoma if ultrasound is unsatisfactory
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast MRI for women, annually starting at 20 years
        </p>
        <p>
        </p>
        <p>
         Some screenings vary regionally (colonoscopies are recommended in the United States but not Europe or Great Britain). Some screenings such as breast MRI may be decreased in older adults, but whole-body MRI is typically continued indefinitely.
        </p>
        <p class="headingAnchor" id="H2715693551">
         <span class="h2">
          Cancer risk reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         No therapies have been clearly demonstrated to reduce cancer risk in individuals with h
         <em>
          TP53
         </em>
         rc. The following may be discussed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consultation with a cancer genetics program will provide important insights on living with the condition and contemporary screening approaches. Patients are often approached to participate in studies to better understand this rare syndrome. (See
         <a class="local">
          'First-degree relatives (testing and counseling)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals undergoing mastectomy for breast cancer may elect to have a bilateral mastectomy to avoid radiotherapy and reduce the very high risk of contralateral breast cancer [
         <a href="#rid14">
          14-17
         </a>
         ]. Risk-reducing bilateral mastectomy may also be considered in young women without breast cancer. (See
         <a class="medical medical_review" href="/z/d/html/94744.html" rel="external">
          "Contralateral prophylactic mastectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is under investigation as a possible chemoprevention approach. Clinicians may contact a hereditary cancer expert to seek updated information or possible enrollment in a clinical trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          Tamoxifen
         </a>
         could be considered for breast cancer risk reduction, although its efficacy in individuals with h
         <em>
          TP53
         </em>
         rc is untested.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding carcinogenic exposures such as smoking seems prudent, although data are limited. Patients should be advised on leading a healthy lifestyle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain cancer therapies are avoided if possible (if an alternative exists) due to an increased risk of promoting second tumors. (See
         <a class="local">
          'Cancer management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4215679086">
         <span class="h2">
          Psychosocial support
         </span>
         <span class="headingEndMark">
          —
         </span>
         h
         <em>
          TP53
         </em>
         rc carries a significant psychological burden due to the unpredictability and potential morbidity of new cancer diagnoses. Psychosocial support may be needed to contend with this distress as well as bereavement linked to cancer diagnoses in the family.
        </p>
        <p>
         Studies have shown reduced adherence to surveillance due to concerns about financial and insurance implications; genetic counseling can provide further information to ensure an informed decision has been made to reduce negative impacts [
         <a href="#rid18">
          18-22
         </a>
         ]. (See
         <a class="local">
          'Locating a genetics specialist or oncologist'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1959910906">
         <span class="h1">
          CANCER MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal cancer treatment in individuals with a heritable
         <em>
          TP53
         </em>
         -related cancer syndrome (h
         <em>
          TP53
         </em>
         rc) is performed by a multidisciplinary team with expertise in h
         <em>
          TP53
         </em>
         rc and/or hereditary cancer syndromes. The following may apply [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early detection may allow avoidance of more toxic therapies and extensive surgeries, especially since some individuals develop second tumors in the same tissue. (See
         <a class="local">
          'Cancer surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation is avoided when possible due to the increased risk of radiation-induced sarcoma, especially under age 30 years. (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome", section on 'Radiation-associated cancers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Breast cancer can be treated with mastectomy rather than lumpectomy plus radiation.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sarcomas often require radiation. The efficacy may be reduced in individuals with h
         <em>
          TP53
         </em>
         rc.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower-grade gliomas may be treated without radiation; higher-grade gliomas generally are treated with radiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crosslinking agents (
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         , psoralen, platinum compounds) may increase the risk of secondary cancers. These should be avoided if possible (if an alternative exists).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2193019796">
         <span class="h1">
          FIRST-DEGREE RELATIVES (TESTING AND COUNSELING)
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a familial variant in
         <em>
          TP53
         </em>
         has been identified, testing first-degree relatives is useful  (
         <a class="graphic graphic_algorithm graphicRef130071" href="/z/d/graphic/130071.html" rel="external">
          algorithm 1
         </a>
         ). Testing as early as infancy is reasonable due to the early age of tumor onset.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A positive finding can facilitate early initiation of cancer surveillance and treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative results allow avoidance of the burdens of surveillance and psychological stress related to increased cancer risk.
        </p>
        <p>
        </p>
        <p>
         Testing should be coordinated with counseling from a specialist (genetic counselor, clinical geneticist, oncologist with expertise in hereditary cancer syndromes) who can provide information about potential results and their implications. In some countries, such as the United Kingdom, only a genetics specialist can request this testing.
        </p>
        <p class="headingAnchor" id="H4126177431">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H2674678979">
         <span class="h2">
          Locating a genetics specialist or oncologist
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following provide listings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=128212" target="_blank">
          Clinical geneticists
         </a>
         – American College of Medical Genetics and Genomics (ACMG)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=128212" target="_blank">
          Genetic counselors
         </a>
         – National Society of Genetic Counselors (NSGC)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         National Institutes of Health (NIH) Cancer Genetics
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=128212" target="_blank">
          Services Directory
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbsgm.org.uk%2Fhealthcare-professionals%2Flist-of-genetic-clinics%2F&amp;token=WPLlYiGN4sfAHHOr06dbfQNyPA4xHbtadkDmHjs5VtRQdilZprvMM9ME4uEsYtBzMrpFwQoE9Ey4MR4UJNV3DXJPAWqPNcIki7sCTU3Gd84%3D&amp;TOPIC_ID=128212" target="_blank">
          Genetic clinics
         </a>
         – British Society for Genetic Medicine
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1285684831">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Li-Fraumeni syndrome (LFS) – (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary breast cancer – (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoma – (See
         <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">
          "Pathogenetic factors in soft tissue and bone sarcomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7734.html" rel="external">
          "Overview of multimodality treatment for primary soft tissue sarcoma of the extremities and superficial trunk"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain tumors – (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6253.html" rel="external">
          "Overview of the management of central nervous system tumors in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5207.html" rel="external">
          "Initial treatment and prognosis of IDH-wildtype glioblastoma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5198.html" rel="external">
          "Treatment and prognosis of IDH-mutant astrocytomas in adults"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batalini F, Peacock EG, Stobie L, et al. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res 2019; 21:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitzel JN, Chao EC, Nehoray B, et al. Somatic TP53 variants frequently confound germ-line testing results. Genet Med 2018; 20:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortuno C, Mester J, Pesaran T, et al. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Hum Mutat 2020; 41:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DG, Turnbull C, Woodward ER. Concern regarding classification of germline TP53 variants as likely pathogenic. Hum Mutat 2019; 40:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Andrade KC, Frone MN, Wegman-Ostrosky T, et al. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis. Hum Mutat 2019; 40:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortuno C, Lee K, Olivier M, et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat 2021; 42:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet 2020; 28:1379.
          </a>
         </li>
         <li class="breakAll">
          https://www.genturis.eu/l=eng/Assets/TP53-Surveillance-Guideline---ERN-GENTURIS-1846.pdf (Accessed on June 17, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kratz CP, Achatz MI, Brugières L, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 2017; 23:e38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson H, Brady AF, Crawford G, et al. UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyder Z, Harkness EF, Woodward ER, et al. Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (&lt;36 Years) Breast Cancer. Cancers (Basel) 2020; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat 2018; 167:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le AN, Harton J, Desai H, et al. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat 2020; 181:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010; 5:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rippinger N, Fischer C, Haun MW, et al. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer 2020; 126:4032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young JL, Pantaleao A, Zaspel L, et al. Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence. J Psychosoc Oncol 2019; 37:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters JA, Kenen R, Bremer R, et al. Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome. J Genet Couns 2016; 25:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lammens CR, Bleiker EM, Aaronson NK, et al. Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits. Fam Cancer 2010; 9:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner-Lin A, Young JL, Wilsnack C, et al. Waiting and "weighted down": the challenge of anticipatory loss for individuals and families with Li-Fraumeni Syndrome. Fam Cancer 2020; 19:259.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128212 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1614522" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cancer. p53, guardian of the genome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31533767" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29189820" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Somatic TP53 variants frequently confound germ-line testing results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32485079" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31016814" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Concern regarding classification of germline TP53 variants as likely pathogenic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30352134" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33300245" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32457520" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32457520" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28572266" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32571901" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32045981" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (&lt;36 Years) Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29039119" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical implications of germline mutations in breast cancer: TP53.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32246378" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21059199" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32557628" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30591002" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26621765" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20658357" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32222840" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Waiting and "weighted down": the challenge of anticipatory loss for individuals and families with Li-Fraumeni Syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
